|
Market Closed -
NYSE
00:00:00 12/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 21.90 USD | -2.36% |
|
-10.06% | -29.35% |
| 08-14 | Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating | MT |
| 08-13 | Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 83.84M | - | - | - | ||
| 994B | |||||
| 640B | - | - | - | ||
| 454B | |||||
| 337B | |||||
| 261B |
Select your edition
All financial news and data tailored to specific country editions
